Shots:
The (REDUCE-IT) trial to evaluate the effect of Vascepa vs PBO in 8179 adult patients with CV disease with LDL-C at ~400 clinical sites in 11 countries
The results showed a reduction in first and total CV events in combined current & former smokers (23% & 29%) in the post hoc exploratory analysis, a reduction in the incidence of CV events in current smokers (23.8%) & former smokers (23.0%) compared with never smokers (25.7%) in the PBO group. The results were presented at ESC 2022 & published in EHJ cardiovascular pharmacotherapy
In Jan 2020, Vascepa has been launched in the US as the first approved therapy for high-risk patients with persistent CV risk after statin therapy
Ref: Globenewswire | Image: Amarin
